Source - RNS
RNS Number : 8035R
LiDCO Group Plc
05 March 2019

LiDCO Group Plc

("LiDCO" or the "Company")


Directorate Change


LiDCO (AIM: LID), the hemodynamic monitoring company, announces the appointment of Tim Hall to the Board as Chief Financial Officer (CFO) and Company Secretary with effect from 11 March 2019.


Tim was CFO of Oxford Gene Technology from 2012 until shortly after its recent acquisition by Sysmex Corporation. Prior to this, Tim was Finance Director at AIM-listed Lombard Medical Technologies PLC for six years and previously had senior finance roles in UCB S.A, Celltech Group plc and Medeva PLC. Tim's early career included finance and project management roles at Glaxo Wellcome plc/ Wellcome plc. Tim qualified as a Chartered Accountant with Touche Ross & Co, now Deloitte.


Tim succeeds Jill McGregor who, as previously announced, leaves LiDCO on 22 March 2019.


Commenting, Matt Sassone, Chief Executive Officer of LiDCO, said: "I am delighted that Tim will be joining LiDCO as CFO and look forward to working with him. He has extensive finance leadership within the med-tech sector and will be a great addition to the Board. I would also like to take this opportunity to thank Jill McGregor for her contribution to the business and to wish her every success in the future."



For further information, please contact:


LiDCO Group Plc

Matt Sassone (CEO)

Tel: +44 (0)20 7749 1500


Tel: +44 (0)20 7600 1658

Geoff Nash / Emily Watts / Hannah Boros (Corporate Finance)

Andrew Burdis (Corporate Broking)

Walbrook PR Ltd

Tel: 020 7933 8780 or [email protected]

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303


The following information is disclosed pursuant to Rule 17 and Schedule Two Paragraph (g) of the AIM Rules for Companies:


Timothy Richard Hall, age 56, holds or has held the following directorships or partnerships in the past five years:


Current Directorships or Partnerships

Previous Directorships or Partnerships


Cytocell Limited

Cytocell Technologies Limited

Oxford Gene Technology Limited

Oxford Gene Technology IP Limited

Oxford Gene Technology (Operations) Ltd

Oxford Gene Technology (Southern) Limited

Oxford Gene Technology EBT Limited


Tim Hall has no shareholding in the Company. It is intended that the Company will grant Tim options over new ordinary shares in the Company.


About LiDCO Group Plc (

LiDCO is a supplier of non-invasive and minimally invasive hemodynamic equipment to hospitals used to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the application of hemodynamic optimisation protocols for high risk patients in both critical care units and in the operating theatre. 


A number of clinical studies have shown that the optimisation of patients' hemodynamic status in high risk patients produces better outcomes and reduced hospital stay.  LiDCO's computer-based technology, originally developed at St Thomas' Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.


Key Products:


LiDCOunity: a hemodynamic monitor that combines the full suite of LiDCO technology (non-invasive, minimally invasive and calibrated technologies) into one platform. Designed to have the flexibility to adapt to a patient's changing acuity, the product enables clinicians to seamlessly transition between non-invasive, minimally invasive and calibrated hemodynamic monitoring.


LiDCOplus: a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%).


LiDCOrapid: a cardiac output monitor designed specifically for use in the operating theatre for fluid and drug management. The monitor enables anaesthetists to receive accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being before, during and after surgery.  The LiDCOrapid provides:


·     early and rapid warning of hemodynamic change to aid choice of therapeutic route: fluid or drug

·     quantification of hemodynamic response guidance on effective delivery of fluids to ensure the right amount at the right time


The software incorporated into LiDCOrapid allows the LiDCOrapid monitor to co-display Medtronic's level of consciousness parameter ('BISTM')* and add the convenience of CNSystem's continuous non-invasive blood pressure monitoring ('CNAP')**. This addresses a growing requirement for non-invasive monitoring solutions that are more comprehensive and can effectively replace multiple single parameter monitors. 


LiDCOview: an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data.


*BISTM and Bispectral Index are trademarks of Medtronic registered in the US and foreign countries.

**CNAPTM is a trademark of CNSystems Medizintechnik AG.


LiDCO monitors use single-patient disposables (sensors or smartcards) and are also available in many markets as a software for service model all of which provide a recurring revenue stream. 


LiDCO Distribution Network:

LiDCO sells directly to hospitals in the UK and USA and through a network of specialty critical care and anaesthesia distributors in the rest of the world.


LiDCO's headquarters are in London and its shares are traded on AIM.



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit